Impressive continuous complete response after mogamulizumab in a heavily pre-treated Sézary syndrome patient
Background: Sézary syndrome (SS) is a rare lymphoproliferative neoplasm, almost incurable outside the setting of allogeneic transplantable patients. Prognosis for relapse/refractory patient remains poor, as the available drugs confer short lasting remission. In this setting, the anti-chemokine recep...
Saved in:
| Main Authors: | Pier Luigi Zinzani, Ginevra Lolli, Beatrice Casadei, Lisa Argnani, Laura Nanni, Michele Cavo |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2020-06-01
|
| Series: | Mediterranean Journal of Hematology and Infectious Diseases |
| Subjects: | |
| Online Access: | http://mjhid.org/index.php/mjhid/article/view/4234 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Mogamulizumab in combination improves clinical outcomes in relapsed and refractory Sézary syndrome
by: Jordan Pilkington, et al.
Published: (2025-05-01) -
Current Opportunities for Treatment Optimization of Mycosis Fungoides and Sezary Syndrome
by: NG Chernova, et al.
Published: (2018-01-01) -
Emergence of bullous pemphigoid under treatment of mycosis fungoides with mogamulizumab
by: Lukas D. Uleer, et al.
Published: (2025-06-01) -
Molecular genetic features of cutaneous T-cell lymphomas development on example of mycosis fungoides and Sezary syndrome
by: M. B. Khadzhieva, et al.
Published: (2022-01-01) -
Unraveling the role of chemokines in cutaneous T-cell lymphoma: expression levels at different stages
by: Alba Guglielmo, et al.
Published: (2025-08-01)